Ann: AVITA Medical to Announce First Quarter 2024 Results, page-134

First 134 Last

Share
Profile

Follow
Melody432

1,248 Posts.

476

24/05/24

04:23

Post #: 73984917
Share

Originally posted by Melody432: ↑

https://academic.oup.com/jbcr/article/44/Supplement_1/S26/6960747

Attached is an article about a study done on synthetic allograft skin substitutes. Permeaderm and several of it's competitor products - Novosorb, Integra and several others - are reviewed as to pros and cons. There are over a dozen competing products out there. Integra has been out there almost 30 years. How many of Avita's accounts will require a VAC process for Permeaderm is also an unkown.
I finally got a chance to read the Stedical agreement last night. I believe the 3.1M was money Stedical needed to take existing product off the hands of it's prior distributor. Although that figure may have included Avita's minimum intial purchase, did not hear any clarification on that in the Q call or webinar. Would seem the prior distributor wasn't selling much. Impossible to know. But JC should know. Maybe he could share with us.
My reading of the contract indicates a 50-50 share of revenues, didn't see anything stating a guaranteed 50% profit. That's a lot different than 50% of revenue. Distribution, marketing and sales cost would come out of Avita's end of sales revenue. If I missed that 50% profit guarantee hope someone will point me to it. Profit guarantees can create difficulties between partners, especially where multiple products are involved. Separating out costs can be tricky and contentious. That's why most of these type agreements are tiered royalties, based on quantity of sales.
The only time royalties would be involved would be if Stedical relocated it's production facility (outside of California? wasn't clear to me) and Avita took over the existing facility. Stedical would only receive a royalty on that portion of product sold. Amount of royalty not stipulated.
All for now. Other topics later. Brain starts to hurt thinking about that webinar. Lots of horse manu.. to deal with there.

Expand

Sorry, not good with smart phones, guess you can copy paste the article to your browser. Glad AI showed up late in my life or I'd have been toast.

AVH Price at posting: $2.66 Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

RAD

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

SGP

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

PAM

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

First 134 Last

Add AVH (ASX) to my watchlist

(20min delay)
Last $3.79		Change 0.060(1.61%)		Mkt cap ! $264.8M

Open	High	Low	Value	Volume
$3.80	$3.83	$3.73	$384.7K	101.5K

Buyers (Bids)

No.	Vol.	Price($)
1	499	$3.79

Sellers (Offers)

Price($)	Vol.	No.
$3.83	17461	2

View Market Depth

No.	Vol.	Price($)
1	499	3.790
1	19	3.780
1	2000	3.750
3	2747	3.730
1	268	3.720

Price($)	Vol.	No.
3.830	17461	2
3.840	1400	2
3.850	1537	3
3.860	11516	4
3.880	1102	2

Last trade - 16.10pm 19/11/2024 (20 minute delay)

AVH (ASX) Chart

Ann: AVITA Medical to Announce First Quarter 2024 Results, page-134

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AVITA Medical to Announce First Quarter 2024 Results, page-134

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

Things finally 'looking different' for up-and-down Hot Stock tip Stockland

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News